Why Is Agios Pharma Stock Falling In Pre-market?
(RTTNews) - Agios Pharmaceuticals (AGIO) announced that the FDA has not yet issued a regulatory decision on the supplemental New Drug Application for mitapivat for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. The company noted that the sNDA remains under active review. The PDUFA goal date issued by the FDA was December 7, 2025.
Agios said the FDA has not provided a timeline for its regulatory decision. The company continues to work with the FDA to conclude the review of the sNDA.
Shares of Agios Pharmaceuticals are down 2.6% to $27.00 in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.